Skip to content
Pharma Observatory a Scientist.com platform

Clinical trial

Phase 1 Dose Escalation, Multi-tumor Study to Assess the Safety, Tolerability and Antitumor Activity of Genetically Engineered MAGE-A4ᶜ¹º³²T in HLA-A2+ Subjects With MAGE-A4 Positive Tumors

NCT03132922 is registered in ClinicalTrials.gov with USWM CT, LLC as lead sponsor.

NCT NCT03132922
Email me this page as a PDF

Search trials, sites, companies and investigators, and follow each one to the others. Individual plan, $249/seat/mo. Card required.

Get the NCT03132922 report as a PDF

The PDF carries up to 50 rows of each section, where the page shows the first few, with the sources listed. Enter a work email and confirm it from the message we send, and the report follows by email.

Registry record

As filed in ClinicalTrials.gov.

Title
Phase 1 Dose Escalation, Multi-tumor Study to Assess the Safety, Tolerability and Antitumor Activity of Genetically Engineered MAGE-A4ᶜ¹º³²T in HLA-A2+ Subjects With MAGE-A4 Positive Tumors
Lead sponsor
USWM CT, LLC
Phase
Phase 1
Overall status
Active, not recruiting
Start date
May 15, 2017
Completion date
September 30, 2032
Enrollment
71 (actual)
Sites
11

Conditions

As the registry lists them; a condition with its own page is linked.

esophageal cancer, gastric cancer, gastroesophageal junction, head and neck cancer, melanoma, myxoid round cell liposarcoma, non-small cell lung cancer, ovarian cancer, synovial sarcoma, urinary bladder cancer